Efficacy and safety of selective vitamin D receptor activation with paricalcitol for reduction of proteinuria in kidney transplant recipients: a randomized controlled trial - Paricalcitol for reduction of proteinuria in kidney transplant recipients

niversity Medical Centre Ljubljana0 个研究点开始时间: 2012年1月10日最近更新: 2012年4月3日

适应症

试验速览

暂无简介。

•Recipients of a deceased donor kidney transplant at least three months after transplantation.
•Patients are on stable immunosuppression at least three months before study enrollment.
•Recipient age = 18 years.
•Patients are on stable doses of antihypertensive medications for at least three months before study enrollment.
•Patients are not expected to begin dialysis for at least six months.
•Estimated glomerular filtration rate > 15 mL/min/1.73 m2.
•UPCR > 22 mg/mmol (> 200 mg/g), as determined by the geometric mean of three second morning void urine samples.
•Corrected serum calcium concentration = 2.5 mmol/L.
•Intact parathoromone concentration > 35 pg/mL.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 156
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•Patients on vitamin D receptor activation therapy within three months prior to the first study visit.
•Patients with diagnosis of primary focal segmental glomerulosclerosis (FSGS).
•Patients with acute kidney injury within three months prior to the first study visit.
•Patients with poorly controlled hypertension (systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg).

发起方

niversity Medical Centre Ljubljana